IRIDEX (IRIX) Raised to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of IRIDEX (NASDAQ:IRIX) from a sell rating to a hold rating in a research note issued to investors on Wednesday morning.

According to Zacks, “IRIDEX Corporation is the leading worldwide provider of semiconductor-based laser systems used to treat eye diseases in ophthalmology and skin lesions in dermatology. The products are sold in the United States predominantly through a direct sales force and internationally through independent distributors. The company markets the products using three brand names: IRIS Medical to the ophthalmology market, IRIDERM to the dermatology market, and Light Solutions to the research market. “

Separately, Roth Capital reiterated a buy rating and issued a $13.00 price target on shares of IRIDEX in a report on Friday, November 3rd.

Shares of IRIDEX (NASDAQ IRIX) traded up $0.16 during trading hours on Wednesday, hitting $7.97. The company’s stock had a trading volume of 8,217 shares, compared to its average volume of 21,115. The stock has a market capitalization of $90.44, a price-to-earnings ratio of -4.66 and a beta of 1.31. IRIDEX has a fifty-two week low of $7.43 and a fifty-two week high of $16.37.

In other IRIDEX news, CEO William M. Moore acquired 5,000 shares of IRIDEX stock in a transaction that occurred on Tuesday, December 12th. The stock was bought at an average price of $7.84 per share, with a total value of $39,200.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.01% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the stock. Neuberger Berman Group LLC bought a new position in IRIDEX in the third quarter worth approximately $141,000. Lyon Street Capital LLC raised its stake in IRIDEX by 4.5% in the third quarter. Lyon Street Capital LLC now owns 442,647 shares of the medical equipment provider’s stock worth $4,148,000 after buying an additional 19,059 shares in the last quarter. Osborne Partners Capital Management LLC acquired a new position in shares of IRIDEX during the third quarter worth $673,000. Ingalls & Snyder LLC acquired a new position in shares of IRIDEX during the third quarter worth $234,000. Finally, Susquehanna International Group LLP acquired a new position in shares of IRIDEX during the second quarter worth $196,000. 49.31% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at


IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).

Get a free copy of the Zacks research report on IRIDEX (IRIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit